NKTR
NEKTAR THERAPEUTICS
Key Financials
Revenue
$55.2M
↓ 43.9%
Net Income
$-164076000
↓ 37.9%
Gross Profit
$623000
↓ 76.4%
Operating Income
$-140102000
↓ 33.2%
Total Assets
$280.4M
↓ 7.7%
Shareholders' Equity
$89.8M
↑ 47.9%
EPS (Diluted)
$-9.73
↓ 1577.6%
Total Liabilities
$190.6M
↓ 21.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| SCHEDULE 13G/A | 9/28/2026 | View on SEC |
| 4 | 9/25/2026 | View on SEC |
| 4 | 9/25/2026 | View on SEC |
| 4 | 9/25/2026 | View on SEC |
| 4 | 9/25/2026 | View on SEC |
| 4 | 9/25/2026 | View on SEC |
| 8-K | 9/25/2026 | View on SEC |
| 8-K | 9/8/2026 | View on SEC |
| 4 | 8/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NKTR |
| Company Name | NEKTAR THERAPEUTICS |
| CIK | 906709 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 4154825300 |